Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metrizamide inhibits human brain hexokinase

J M Bertoni

    Neurology
    |August 1, 1982
    PubMed
    Summary

    Metrizamide, a contrast agent, impairs brain glucose metabolism by inhibiting hexokinase. Co-administration with glucose may counteract these confusional side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Consequences of hypothyroidism on auditory system function in Tshr mutant (hyt) mice.

    Journal of the Association for Research in Otolaryngology : JARO·2002
    Same author

    Development of auditory brainstem responses (ABRs) in Tshr mutant mice derived from euthyroid and hypothyroid dams.

    Journal of the Association for Research in Otolaryngology : JARO·2002
    Same author

    Prevention of auditory dysfunction in hypothyroid Tshr mutant mice by thyroxin treatment during development.

    Journal of the Association for Research in Otolaryngology : JARO·2002
    Same author

    Hyperacute ischemic stroke missed by diffusion-weighted imaging.

    AJNR. American journal of neuroradiology·1999
    Same author

    Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group.

    Archives of neurology·1998
    Same author

    Descriptive epidemiology of Parkinson's disease through proxy measures.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1996

    Area of Science:

    • Neuroscience
    • Biochemistry

    Background:

    • Metrizamide is a myelographic contrast agent known to cause temporary confusional states in patients.
    • Metrizamide's structural similarity to 2-deoxyglucose suggests potential interference with glucose metabolism.

    Purpose of the Study:

    • To investigate the inhibitory effects of metrizamide on human brain glucose metabolism.
    • To determine if glucose co-administration can mitigate metrizamide-induced metabolic impairment.

    Main Methods:

    • Enzyme kinetics assays were performed using human brain hexokinase.
    • The effect of varying metrizamide concentrations (0, 16, and 32 mM) on hexokinase activity was measured.
    • Michaelis constant (Km) and maximal velocity (Vmax) were determined.

    Main Results:

    • Metrizamide significantly increased the Michaelis constant (Km) for glucose in human brain hexokinase, indicating competitive inhibition.
    • The Km values rose from 0.039 mM (control) to 0.24 mM and 0.47 mM at 16 mM and 32 mM metrizamide, respectively.
    • Metrizamide did not alter the maximal velocity (Vmax) of the hexokinase reaction.

    Conclusions:

    • Metrizamide competitively inhibits human brain hexokinase, leading to impaired glucose metabolism.
    • Given the high concentrations of metrizamide used in cerebrospinal fluid (CSF), significant impairment of brain glucose metabolism is likely.
    • Co-injection of metrizamide with a 100 mM glucose solution could potentially counteract these inhibitory effects.

    Related Experiment Videos